



ozonpharm.ru/en

2024

Ozon Pharmaceuticals, founded in 2001, is one of the leading companies in Russia in the production of generics. The Group produces a wide range of pharmaceutical products in different forms: solid, soft, liquid, and sterile.

Production capacity of manufacturing sites



Ozon Pharmaceuticals
378 million packs/year



Ozon PHARM
284 million packs/year



Ozon MEDICA
UNDER CONSTRUCTION




MABSCALE
46 million vials/year

Ozon Pharmaceutical on the map

Distance from Moscow to Samara - 1060 km

Distance from Samara to Togliatti – 90 km

Distance from Ozon to Ozon Pharm – 60 km



The product portfolio is based on the most popular, dynamically developing products.
The Company's product line expands every year.



508

dossiers

of the drug products
are registered in Russia



more than

300

million packs

of the drug products
are produced per year



more than

1300

tonnes

of APIs are
purchased annually



more than

56

million USD

are spent on
purchases
of API annually



more than

32

million USD

are spent on purchases
of excipients and
packaging annually

Ozon Pharmaceutical Team

Group of company number of staff more than
All production sites

2700

R&D Team

Search and registration

68

Quality Department Team, more than
including:

380

QC department, more than

130

Labs, more than

180

Purchasing team

Both direct & indirect materials

41


Ozon Pharmaceutical IPO

Ozon Pharmaceutical has changed its legal form to Public Stock Company.


17th of October stock trading started on the Moscow Stock Exchange.

Ticker – OZPH.





Sales volume (packs/year)




Sales volume (USD/year)

Leading corporations in pharmaceutical drug product sales in the Russian commercial market in 2023


We are in the **TOP10**
of Russian market share

By value



Leading corporations in pharmaceutical drug product sales in the Russian commercial market in 2023

By volume



The 2nd place

in pharmaceutical drug product sales in packs for 2023

Pharmstandard	305 000 000
---------------	-------------

OZON	285 200 000
-------------	--------------------

Stada	176 300 000
-------	-------------

Leading corporations in RX pharmaceutical drug product sales in the Russian retail commercial market (SELL-OUT) in 2023:

By value



We have contracts with **80%**
of the Pharmacy chains across Russia

Ozon production sites and products have already been successfully registered or are in the process of registration in the following countries:

Major market



Russia

Foreign market



UAE



Philippines



Vietnam



Mongolia



Kazakhstan



Pakistan



Uzbekistan



Morocco



Syria



Yemen

Our partners:



and many more...



ozonpharm.ru/en